← Leaderboards
Michael Jordan
Cincinnati Childrens Hosp Med Ctr
$6,618,086
Attributed
$7,612,586
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,040,396 · 7
FDA$1,572,190 · 1
By mechanism
R01$5,286,213 · 3
R21$1,270,619 · 3
R34$677,484 · 1
K08$378,270 · 1
Top collaborators
- David A Hildeman4 shared
- Andrew B Herr2 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Rebecca Marsh$1,164,079
- Andrew B Herr$9,697,508
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteImmuneBaseResponseInsightGeneticCellsMutationPerforinKillingsAntigensBone Marrow TransplantationVirus DiseasesCytotoxicLymphocytic Choriomeningitis VirusGenesIn VivoSyndromeHemophagocytic LymphohistiocytosesImmune ResponseAffectDendritic CellsPathogenesisInfection
Grant awards (27)
Abatacept for the treatment of Common Variable Immunodeficiency with Interstitial Lung Disease (ABCVILD) IND #152820 9/2/20$529,803
R01 · FY2025 · FD · contact PI
Abatacept for the treatment of Common Variable Immunodeficiency with Interstitial Lung Disease (ABCVILD) IND #152820 9/2/20$227,058
R01 · FY2023 · FD · contact PI
Redefining hemophagocytic lymphohistiocytosis in hematologic malignancies$218,538
R21 · FY2022 · CA · contact PI
Abatacept for the treatment of Common Variable Immunodeficiency with Interstitial Lung Disease (ABCVILD) IND #152820 9/2/20$815,329
R01 · FY2021 · FD · contact PI
Redefining hemophagocytic lymphohistiocytosis in hematologic malignancies$185,831
R21 · FY2021 · CA · contact PI
Targeted manipulation of the DNA damage response for prevention/treatment of GVHD$198,750
R21 · FY2020 · AI · contact PI
Targeted manipulation of the DNA damage response for prevention/treatment of GVHD$238,500
R21 · FY2019 · AI · contact PI
Mechanisms of LRBA-mediated control of CTLA4$195,000
R21 · FY2018 · AI · contact PI
Exploiting the DNA damage response to selectively sculpt the T cellrepertoire$390,000
R01 · FY2017 · AI · contact PI
Mechanisms of LRBA-mediated control of CTLA4$234,000
R21 · FY2017 · AI · contact PI
Exploiting the DNA damage response to selectively sculpt the T cellrepertoire$390,000
R01 · FY2016 · AI · contact PI
Exploiting the DNA damage response to selectively sculpt the T cellrepertoire$390,000
R01 · FY2015 · AI · contact PI
Exploiting the DNA damage response to selectively sculpt the T cellrepertoire$390,000
R01 · FY2014 · AI · contact PI
Hybrid ImmunoTherapy (ATG/Dexamethasone/Etoposide) for Hemophagocytic Lymphohisti$229,500
R34 · FY2014 · HL · contact PI
Hybrid ImmunoTherapy (ATG/Dexamethasone/Etoposide) for Hemophagocytic Lymphohisti$218,484
R34 · FY2013 · HL · contact PI
Hybrid ImmunoTherapy (ATG/Dexamethasone/Etoposide) for Hemophagocytic Lymphohisti$229,500
R34 · FY2012 · HL · contact PI
An Animal Model of Hemophagocytic Lymphohistiocytosis$375,000
R01 · FY2011 · HL · contact PI
An Animal Model of Hemophagocytic Lymphohistiocytosis$375,000
R01 · FY2010 · HL · contact PI
An Animal Model of Hemophagocytic Lymphohistiocytosis$15,000
R01 · FY2010 · HL · contact PI
An Animal Model of Hemophagocytic Lymphohistiocytosis$375,000
R01 · FY2009 · HL · contact PI
An Animal Model of Hemophagocytic Lymphohistiocytosis$249,023
R01 · FY2009 · HL · contact PI
An Animal Model of Hemophagocytic Lymphohistiocytosis$15,000
R01 · FY2009 · HL · contact PI
An Animal Model of Hemophagocytic Lymphohistiocytosis$375,000
R01 · FY2008 · HL · contact PI
An Animal Model of Hemophagocytic Lymphohistiocytosis$375,000
R01 · FY2007 · HL · contact PI
B Cell Expansion After Dendritic Cell Immunization$126,090
K08 · FY2004 · AI
B Cell Expansion After Dendritic Cell Immunization$126,090
K08 · FY2003 · AI
B Cell Expansion After Dendritic Cell Immunization$126,090
K08 · FY2002 · AI